Director, Bioconjugation

Role: Senior scientific leader as Director of Bioconjugation, focusing on antibody-drug conjugates (ADCs) and antibody–RNA conjugates (ARCs/AOCs). Objectives include defining bioconjugation strategies, leading a team of scientists, and partnering across disciplines to advance conjugate therapeutics from target selection through candidate nomination and transition to development. Responsibilities encompass setting the bioconjugation platform strategy, overseeing chemistry, linker-payload design, and conjugation technology, as well as managing external collaborations. Requirements: PhD in chemistry, biochemistry, or related, with 8+ years in industry or academia, including at least 6 years in leadership roles. Deep expertise in bioconjugation chemistry—cysteine/lysine conjugation, site-specific and enzymatic methods, click chemistry—and experience with cytotoxic payloads, oligonucleotide conjugates, and degrader platforms. Proven track record in advancing discovery programs to clinical candidates, with strong analytical skills (RP-HPLC, SEC, LC-MS). Preferred qualifications include leadership in discovery project teams, oligonucleotide therapeutics, glycan-mediated platforms, and CMC/tech transfer experience supporting IND-enabling packages. High-value specifics: antibody conjugates, payload diversity (small molecules, oligonucleotides, degraders), therapeutic areas, and portfolio strategy. Collaboration: cross-functional with Discovery Chemistry, Biology, DMPK, Toxicology, and external partners. Work setup: location not explicitly specified, likely hybrid or onsite given the role’s strategic leadership and collaboration scope.